
Danish biotech company Orphazyme, which is currently undergoing an in-court restructuring of its organization, reports that trading of its American Depositary Shares (ADSs) will terminate on July 6, a company press release has announced. Secondary trading of these assets ended last Friday.
Orphazyme writes that it has received a notification from the Bank of New York Mellon, saying that holders of American Depositary Receipts (ADRs), which represent proof of ownership of Orphazyme ADSs, have been notified of the termination date on April 5.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app